Home・Aktien・Lantheus Holdings Inc

Lantheus Holdings Inc

Open

BrancheGesundheitswesen

100.1 -0.15

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

99.98

Max

100.47

Schlüsselkennzahlen
By Trading Economics
Einkommen	75M 193M
Verkäufe	11M 388M
KGV Branchendurchschnitt	24.156 56.597
EPS	1.32
Gewinnspanne	49.834
Angestellte	1,193
EBITDA	-69M 115M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+5.14% upside

Dividenden
By Acuity
Nächstes Ergebnis	5. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	2.5M 6.6B
Vorheriger Eröffnungskurs	100.25
Vorheriger Schlusskurs	100.1

Nachrichtenstimmung

By Acuity

60%

40%

273 / 339 Ranking in Healthcare

Lantheus Holdings Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Lantheus Holdings Inc Prognose

Kursziel

By TipRanks

5.14% Vorteil

12-Monats-Prognose

Durchschnitt 105.4 USD 5.14%

Hoch 115 USD

Tief 102.5 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Lantheus Holdings Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

10 ratings

Buy

Halten

Sell

Basierend auf 10 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Lantheus Holdings Inc – Dist abgegeben haben.

Stimmung

By Acuity

273 / 339 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.